Wolfson Palliative Care Research Centre, University of Hull, Hull, United Kingdom.
Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom.
PLoS One. 2021 Jan 28;16(1):e0245647. doi: 10.1371/journal.pone.0245647. eCollection 2021.
People with cancer often have unidentified symptoms and social care needs. The Needs Assessment Tool-Cancer (NAT-C) is a validated, structured method of assessing patient/carer concerns and prompting action, to address unmet need.
Assess feasibility and acceptability of a definitive two-armed cluster randomised trial of NAT-C in primary care by evaluating: recruitment of GP practices, patients and carers; most effective approach of ensuring NAT-C appointments, acceptability of study measures and follow-up.
Non-blinded, feasibility study in four General Practices, with cluster randomisation to method of NAT-C appointment delivery, and process evaluation. Adults with active cancer were invited to participate with or without carer. Practices cluster randomised (1:1) to Arm I: promotion and use of NAT-C with a NAT-C trained clinician or Arm II: clinician of choice irrespective of training status. Participants completed study questionnaires at: baseline, 1, 3 and 6 months. Patients booked a 20 minute needs-assessment appointment post-baseline. Patients, carers and GP practice staff views regarding the study sought through interviews/focus groups. Quantitative data were analysed descriptively. Qualitative data were analysed thematically, informed by Normalisation Process Theory. Progression to a definitive trial was assessed against feasibility outcomes, relating to: recruitment rate, uptake and delivery of the NAT-C, data collection and quality.
Five GP practices approached, four recruited and trained to use the NAT-C. Forty-seven participants and 17 carers recruited. At baseline, 34/47 (72%) participants reported at least one moderate-severe unmet need, confirming study rationale. 32/47 (68%) participants received a NAT-C-guided consultation, 19 of which on Arm I. Study attrition at one month (n = 44 (94%), n = 16 (94%)), three months (n = 38 (81%), n = 14 (82%)) and six months (n = 32 (68%), n = 10 (59%)). Fifteen patient interviews conducted across the whole study and one focus group at each GP practice. Participants supported a definitive study and found measures acceptable.
The feasibility trial indicated that recruitment rate, intervention uptake and data collection were appropriate, with refinements, for a definitive multi-centre cluster randomised controlled trial. Feasibility outcomes informed the design of a 2-armed cluster randomised controlled trial to test the effectiveness and cost-effectiveness of the NAT-C compared with usual care.
癌症患者常有未确诊的症状和社会护理需求。需求评估工具-癌症(NAT-C)是一种经过验证的结构化方法,用于评估患者/照顾者的关注点并提示采取行动,以满足未满足的需求。
通过评估以下方面,评估在初级保健中进行 NAT-C 的确定性两臂聚类随机试验的可行性和可接受性:全科医生实践、患者和照顾者的招募;确保 NAT-C 预约最有效的方法、研究措施和随访的可接受性。
在 4 家普通诊所进行非盲、可行性研究,采用聚类随机分组,比较 NAT-C 预约交付的方法,并进行过程评估。邀请患有活动性癌症的成年人及其照顾者参加,无论是否有照顾者。实践聚类随机(1:1)至 Arm I:使用经过 NAT-C 培训的临床医生推广和使用 NAT-C 或 Arm II:临床医生选择,无论培训状况如何。参与者在基线、1、3 和 6 个月时完成研究问卷。患者在基线后预约 20 分钟的需求评估预约。通过访谈/焦点小组了解患者、照顾者和全科医生实践工作人员对研究的看法。定量数据进行描述性分析。定性数据根据正常化过程理论进行主题分析。根据可行性结果评估向确定性试验的进展,涉及招募率、NAT-C 的接受和提供、数据收集和质量。
接触了 5 家全科医生实践,其中 4 家接受了培训并使用了 NAT-C。招募了 47 名参与者和 17 名照顾者。在基线时,34/47(72%)名参与者报告至少有一项中度至重度未满足的需求,证实了研究的合理性。32/47(68%)名参与者接受了 NAT-C 指导的咨询,其中 19 名在 Arm I 中。一个月时的研究失访率(n = 44(94%),n = 16(94%))、三个月(n = 38(81%),n = 14(82%))和六个月(n = 32(68%),n = 10(59%))。整个研究共进行了 15 次患者访谈和每个 GP 实践的一次焦点小组。参与者支持确定性研究并认为措施可以接受。
可行性试验表明,招募率、干预接受率和数据收集率适当,需要进一步改进,以进行确定性多中心聚类随机对照试验。可行性结果为设计 2 臂聚类随机对照试验提供了信息,以测试与常规护理相比,NAT-C 的有效性和成本效益。